

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

December 17, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO (Securities code: 4576; TSE Growth)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement of Launch in Malaysia for Glaucoma and Ocular Hypertension  
Treatment “GLA-ALPHA® Combination Ophthalmic Solution (Japanese  
product name)”

D. Western Therapeutics Institute, Inc. (hereafter, “DWTI”) hereby announces that Kowa Co., Ltd., to which DWTI out-licensed its in-house discovered Rho-kinase inhibitor ripasudil hydrochloride hydrate, commenced sales in Malaysia of the glaucoma and ocular hypertension treatment “GLA-ALPHA® Combination Ophthalmic Solution” (generic name: ripasudil hydrochloride hydrate/brimonidine tartrate)” (hereafter, “this drug”), a new fixed combination eye drop.

This drug is the world’s first fixed combination eye drop containing ripasudil hydrochloride hydrate, the active pharmaceutical ingredient in Rho-kinase inhibitor GLANATEC® ophthalmic solution 0.4%, and  $\alpha$ 2-adrenergic agonist brimonidine tartrate. Since the drug has a different site of action than existing combination eye drops, it can be used in combination with various other treatments for glaucoma and ocular hypertension.

Kowa has been marketing this drug in Japan since December 2022, and sales are steadily increasing. Since receiving approval in Japan, Kowa has been promoting overseas development, and sales began in Thailand in July 2025. Approval has now also been obtained in Singapore, and Kowa is continuing to consider further overseas expansion.

This product will provide patients in Malaysia with a new treatment option, contribute to the important control of intraocular pressure in the treatment of glaucoma and ocular hypertension, and help improve adherence in patients who require multiple ophthalmic medications.

As we advance, we will receive royalties based on the agreement; however, as the impact on the current fiscal year’s performance is expected to be minimal, there is no revision to the earnings forecast for the fiscal year ending December 2025 at this time.

End